Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Cornerstone Therapeutics

- PMLiVE

Chiesi report highlights incorrect inhaler use among UK asthma patients

The long-term lung condition affects around 7.2 million people in the UK

- PMLiVE

Chiesi Group invests €400m to establish biotech centre of excellence in Italy

The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

- PMLiVE

Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa

Rare diseases currently affect around 436,000 people living in Scotland

- PMLiVE

NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

- PMLiVE

NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

Affecting approximately 1,150 people in England, Fabry disease is a rare genetic disease that can lead to progressive damage to vital organs

Patient Centric Approaches for Rare and Ultra-Rare Diseases

Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale....

Impetus Digital

- PMLiVE

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme

- PMLiVE

Moderna inks R&D agreements with Vertex and Chiesi

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

- PMLiVE

Chiesi launches new rare disease R&D division

New business unit will be based in Boston, US

- PMLiVE

NICE backs Europe’s first stem cell therapy

Holoclar is approved for routine use in patients with LSCD

- PMLiVE

Chiesi’s Holoclar wins UK Prix Galien orphan drug award

Novartis and Astellas also scoop prizes at the prestigious ceremony

- PMLiVE

Cell Therapy licenses heart failure therapy in Japan

EMA may grant Welsh-based biotech a marketing application in mid-2016

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links